ABSTRACT
Emerging markets refer to countries, such as China, Brazil, Russia, India, Mexico, Indonesia, and Turkey [1]. Because of these countries’ economic achievements, the need for drug development in these emerging markets receives great attention because of their market potentials and patient resources. Because the emerging market countries desire to benefit from newly developed drugs, the regulatory authorities of these countries require the efficacy and safety evidence of the new drugs in the patient population of their countries. Therefore, some of the clinical data of the new drug development will be from the emergent markets. Furthermore, the updated standards for drug development in developed countries require a greater sample size than before, which also requires clinical trials for new drug development to be expanded to the emergent markets.
